以肿瘤病理学为主要研究领域，聚焦于化疗药物诱导的多种细胞死亡形式的分子机制，关注基因调控与细胞周期进展，从表观遗传修饰的角度探讨肿瘤增殖及治疗抵抗的病理机制，并研发靶向干预策略。

Dr. Du specializes in tumor pathology, focusing on the molecular mechanisms underlying various forms of cell death induced by chemotherapeutic agents. His research also emphasizes gene regulation and cell cycle progression, exploring the pathological mechanisms of tumor proliferation and treatment resistance from the perspective of epigenetic modification, and developing targeted intervention strategies.

同济大学附属第一妇婴保健院病理科主任

中国抗癌协会肿瘤病理专委会委员

上海市病理学会分子病理学组委员

Director of the Department of Pathology, First Maternity and Infant Health Hospital Affiliated to Tongji University

Member of the Tumor Pathology Committee, Chinese Anti-Cancer Association

Member of the Molecular Pathology Group, Shanghai Society of Pathology

迄今已以（共同）第一或通讯作者身份发表研究论文20余篇，其中包括Cancer Lett，J Exp Clin，Cancer Res等国际知名学术期刊，主持国家自然基金2项，已获授权发明专利1项。

Dr. Du has published more than 20 manuscripts as the first or corresponding author, including in internationally renowned journals such as Cancer Lett and J Exp Clin Cancer Res. He has also hosted 2 projects of National Natural Science Foundation of China and has been granted 1 invention patent.

【主持科研项目】

线粒体RNA触发免疫应答在烷化剂免疫原性化疗中的作用及机制.。上海自然科学基金，20万，（2024.10-2027.9）

p16/ki67免疫组化双染在宫颈癌筛查异常人群中的检测及其对妊娠期宫颈高级别病变的诊断价值。中国高校产学研创新基金，10万，（2024.4-2025.4）

浦东新区妇产科病理诊断联盟优化项目。浦东医联体项目，5万，（2024.12-2025.12）

HER2免疫组化染色病理数智化在乳癌精准诊断中的关键技术研究及临床应用。同济大学"医学+X"交叉研究项目，20万，（2025.1-2028.1）

FTO在蒽环类药物诱导的乳腺癌免疫性细胞死亡中的作用及机制，国家自然科学基金委员会面上项目，结题。

Snai1/slug-miR30a反馈环路对肾小管上皮细胞间质转化调控，国家自然科学基金委员会青年项目，结题。

纳米金上调miR-145逆转胶质瘤干细胞化疗耐药的研究。广东省自然科学基金，结题。

负载poly(I:C)的纳米金诱导胶质瘤干细胞自主分泌I型干扰素提高替莫唑胺敏感性。广州市科技计划项目，结题。

内源性逆转录病毒在蒽环类化疗药物诱导的抗肿瘤免疫反应中的作用。广东省医学科学基金项目，结题。

【发表研究论文】

(1) Li C, Xu X, Zhao X, Du B. The inconsistent pathogenesis of endometriosis and adenomyosis: insights from endometrial metabolome and microbiome. mSystems. Published online April 22, 2025.

(2) Tao S; Xie SJ; Diao LT; Lv G; Hou YR; Hu YX; Xu WY; Du B*; Xiao ZD*. RNA-binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non-canonical role of DGCR8 in mRNA localization, J Exp Clin Cancer Res., 2023;42(1):194

(3) Jiang S; Wang H; Zhu J; Xu X; Chen L; Wang B; Zhou B; Zhu Y; Zhang Z; Ma B*; Du B*; Yang Y*. Identify the Clinicopathological Characteristics of Lung Carcinoma Patients Being False Negative in Folate Receptor Based Circulating Tumor Cell Detection. Small Methods. 2023;7(9):e2300055

(4) Qu J; Yu J; Zhong S; Wang W; Wang Q; Du B. The presence of clear cell glands around the ovarian endometrioid cyst has an association with clear cell carcinoma. Virchows Arch., 2023;482(6):1021-1034

(5) Shi H; Hou B; Li H; Zhou H; Du B. Cyclophosphamide Induces the Ferroptosis of Tumor Cells Through Heme Oxygenase-1, Front. Pharmacol., 2022, 13: 839464

(6) Li H; Zhong Y; Cao G; Shi H; Liu Y; Li L; Yin P; Chen J; Xiao Z*; Du B*. METTL3 promotes cell cycle progression via m6A/YTHDF1-dependent regulation of CDC25B translation, Int J Biol Sci., 2022, 18(8): 3223-3236

(7) Hu J; Yu X; Yin P; Du B*; Cai X*. Intravoxel Incoherent Motion Diffusion- Weighted MR Imaging for Monitoring the Immune Response of Immunogenic Chemotherapy. Front Oncol. 2022;12:796936.

(8) Du B; Waxman DJ; Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models. Cancer Lett., 2020;470:170-180

(9) Yin P; Li H; Ke C; Cao G; Xin X; Hu J; Cai X; Li L; Liu X*; Du B*. Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response [published correction appears in Int J Nanomedicine. 2020, 15:8873-8874

(10) Cao G; Li S; Shi H; Yin P; Chen J; Li H; Zhong Y; Diao LT*; Du B*. Schisandrin B attenuates renal fibrosis via miR-30e-mediated inhibition of EMT. Toxicol Appl Pharmacol., 2019, 385:114769

(11) Chen J; Du B. Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression. J Cancer Res Clin Oncol. 2019, 145(1):19-29.

(12) Du B; Dai X; Li S; Guo L; Cao G; Zhong Y; Yin P; Yang X. MiR-30c regulates cisplatin-induced apoptosis of renal tubular epithelialcells by targeting Bnip3L and Hspa5, Cell Death & Disease, 2017, 8(8): e2987

(13) Dai X#; Fang M#; Li S; Yan Y; Zhong Y; Du B*. miR-21 is involved in transforming growth factor β1-induced chemoresistance and invasion by targeting PTEN in breast cancer. Oncol Lett., 2017, 14(6):6929-6936

(14) Liu Z, Dai X, Du B*. Hes1: a key role in stemness, metastasis and multidrug resistance. Cancer Biol Ther., 2015, 16(3):353-9

(15) Zhang E; Wang S; Ma J; Li H; Ye J; Xie S; Du B*; Zhong X*. EGCG Inhibits Properties of Glioma Stem-like Cells and Synergizes with Temozolomide through down-regulation of P-glycoprotein Inhibition. Journal of Neuro-Oncology, 2015; 121(1):41-52

(16) Liu Z; Dai X; Du B. Hes1: a key role in stemness, metastasis and multidrug resistance. Cancer Biol Ther. 2015;16(3):353-359

(17) Xiao X; Liao X; Qiu S; Liu Z; Du B*; Xu S*. Synthesis, Cytotoxicity and Apoptosis Induction in Human Tumor Cells by Galaxamide and Its Analogues., Mar Drugs. 2014, 12(8), 4521-4538

(18) Pan Y*; Wu Q; Qin L; Cai J; Du B*. Gold nanoparticles inhibit VEGF165-induced migration and tube formation of endothelial cells via the Akt pathway. Biomed Res Int. 2014;2014:418624.

(19) Pan Y*; Ding H; Qin L; Zhao X; Cai J; Du B*. Gold nanoparticles induce nanostructural reorganization of VEGFR2 to repress angiogenesis. J Biomed Nanotechnol., 2013, 9(10):1746-56

(20) Du B; Yang Z; Zhong X; Fang M; Yan Y; Qi G; Pan Y; Zhou X. Metastasis- associated protein 1 induces VEGF-C and facilitates lymphangiogenesis in colorectal cancer. World J Gastroenterol. 2011;17(9):1219-1226

(21) Du B; Zhong X; Liao X; Xu W; Zhou X; Xu S. A new antitumor arabinopyranoside from Laurencia majuscula induces G2/M cell cycle arrest. Phytother Res. 2010;24(10):1447-1450

【获得授权专利】

(1) 杜彬; 殷培迪; 李惠峰; 曹广旭; 陈嘉玲; AuNP@PP/poly(I:C)及其制备方法与其在制备治疗胶质瘤药物中的应用, 2019-6-21,中国, ZL 201910540889.5 (专利)